Contemporary advances in therapeutic portfolio of 2-Azetidinones

  • Rajneesh Kaur Maharishi Markandeshwar (Deemed to be University)
  • Dr. (Mrs.) Raman Singh Maharishi Markandeshwar (Deemed to be University)
  • Priyanka Ahlawat Maharishi Markandeshwar (Deemed to be University)
  • Parul Kaushik Maharishi Markandeshwar (Deemed to be University)
  • Kuldeep Singh Maharishi Markandeshwar University
Keywords: β-lactams, monobactam, antimicrobial drug resistance, biological activity, multi target drugs

Abstract

The heterocycle moieties form the site of reaction in many enzymes and co-enzymes and also act as an important pharmacophore in the pharmaceutical drug designs. 2-Azetidinones are the 2-carbonyl derivatives of azetidine, more commonly known as β-lactams. These structural entities occupied a central role in the vigil against bacterial infections over the past few decades. A subclass of these heterocyclic systems, monobactams or monocyclic β-lactam derivatives exhibits several biological activities including antibacterial, antifungal, antiprotozoal, anti-mycobacterial, anti-HIV, antiviral, antimalarial, antioxidant, apoptotic inhibitors, anti-inflammatory activity, anticancer activity, herbicidal activity, etc. Monobactams has resistant to the β-lactamase enzyme and could be a reasonable starting point for developing new drugs or inhibitors. In the present review, pharmacological activities of monocyclic β-lactam derivatives have been discussed with respect to current research in the structure-activity relationships in different therapeutic areas.

b-lactam derivatives
Published
2020-01-06
How to Cite
Rajneesh, K., Singh, R., Ahlawat, P., Kaushik, P., & Singh, K. (2020). Contemporary advances in therapeutic portfolio of 2-Azetidinones. Chemical Biology Letters, 7(1), 13-26. Retrieved from http://thesciencein.org/journal/index.php/cbl/article/view/98
Section
Review Articles

Most read articles by the same author(s)